Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2020-09-09 Legal Proceedings Report
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(고형암 환자 대상 'CBT101'의 1상 임상시험계획 승인)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It specifically announces the approval of a Phase 1 clinical trial for the drug 'CBT101' by the Ministry of Food and Drug Safety (MFDS). Since this is a specific regulatory disclosure of a material event (clinical trial approval) that does not fit into the other specialized categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2020-09-09 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service in South Korea. It details the share ownership, changes in shareholding, and collateral agreements (stock-backed loans) of the major shareholder (Cha Kwang-yul) and his special related parties in the company 'Cha Biotech'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks changes in significant ownership levels and related contractual obligations.
2020-08-21 Korean
반기보고서 (2020.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '차바이오텍' covering the period from January 1, 2020, to June 30, 2020. It contains detailed financial information, corporate structure, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). It is not a mere announcement or certification, as it provides substantive financial and operational data. H1 2020
2020-08-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the shareholding status of a major shareholder (Cha Kwang-yul) and special related parties in the company 'Cha Biotech'. This document type is used to notify the market of significant changes in ownership and is classified under 'Major Shareholding Notification' (MRQ) in the provided schema.
2020-07-24 Korean
투자판단관련주요경영사항('퇴행성 요추 추간판으로 인한 만성 요통 환자'에 대한 'CordSTEM-DD'의 임상 1/2a상 임상시험계획의 변경 승인)
Regulatory Filings Classification · 95% confidence The document is a formal regulatory disclosure from a Korean company (Cha Biotech) regarding the approval of a clinical trial plan amendment by the Ministry of Food and Drug Safety (MFDS). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean stock market (KOSPI/KOSDAQ). Since it details a specific regulatory event regarding clinical trials and does not fit into specific categories like financial reports or dividend notices, it is classified as a general regulatory filing.
2020-07-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed under the Capital Markets Act in South Korea. It details changes in share ownership, including the identity of the major shareholder (Cha Kwang-yul), special related parties, and specific details regarding stock collateral contracts. This type of filing is specifically designed to notify the market of significant changes in shareholding thresholds and ownership structure, which falls under the 'Major Shareholding Notification' category.
2020-07-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.